Loading clinical trials...

Fast Discharge After Acute Myocardial Infarction Discharge MI | Clinical Trials | Clareo Health

RECRUITINGNA

Fast Discharge After Acute Myocardial Infarction Discharge MI

Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial

NCT06744322•Medical University Innsbruck

Summary

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (\>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

Detailed Description

The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge \>36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
•Age ≥ 18 years at time of consent
•Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
•Ability to understand and willingness to sign and date written informed consent

Exclusion Criteria

•Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
•PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
•Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
•Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
•Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema)
•Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
•Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
•Pregnancy
•Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
•Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Locations (8)

Hospital Wiener Neustadt

Wiener Neustadt, Lower Austria, Austria

Paracelsus Medical University Salzburg

Salzburg, Salzburg, Austria

Cardinal Schwarzenberg Hospital Schwarzach

Schwarzach im Pongau, Schwarzach Im Pongau, Austria

Medical University of Graz

Graz, Styria, Austria

Medical University of Innsbruck

Innsbruck, Tyrol, Austria

University Teaching Hospital Wels-Grieskirchen

Wels, Upper Austria, Austria

Academic Teaching Hospital Feldkirch

Feldkirch, Vorarlberg, Austria

Ludwig Maximilian University Munich

Munich, Bavaria, Germany

Key Dates

Start Date

December 1, 2024

Primary Completion Date

December 31, 2029

Completion Date

December 31, 2029

Last Updated

March 16, 2026

Enrollment

2,070

ESTIMATED participants

Conditions

Acute Myocardial Infarction (AMI)

Interventions

Fast discharge strategy

PROCEDURE

Contacts

Martin Reindl, MD, PhD

CONTACT

+43 512 504 25665 martin.reindl@tirol-kliniken.at

Ivan Lechner, MD, PhD

CONTACT

ivan.lechner@tirol-kliniken.at

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281

Cardiovascular RiskAcute Myocardial Infarction (AMI)

View study

RECRUITING

Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients

NCT07042321

Acute Myocardial Infarction (AMI)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fast Discharge After Acute Myocardial Infarction Discharge MI

Inclusion Criteria

Exclusion Criteria

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients

Myocardial Infarction and Periodontitis: Periodontal Health Intervention.

Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases

Acute MI Staging Diagnosis by High-sensitivity Cardiac Troponin-I

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction